• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    3/11/24 9:05:55 AM ET
    $AIMD
    $APRE
    $ATXI
    $DYAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million.
    • Dyadic International (NASDAQ:DYAI) stock rose 21.73% to $1.68. The company's market cap stands at $48.4 million.
    • Mesoblast (NASDAQ:MESO) shares rose 19.53% to $2.57. The company's market cap stands at $260.8 million.
    • Aprea Therapeutics (NASDAQ:APRE) stock moved upwards by 15.28% to $8.22. The market value of their outstanding shares is at $30.7 million.
    • Talphera (NASDAQ:TLPH) stock increased by 13.77% to $1.28. The market value of their outstanding shares is at $21.7 million. The company's, Q4 earnings came out 3 days ago.
    • Graphite Bio (NASDAQ:GRPH) stock rose 12.1% to $3.52. The company's market cap stands at $204.9 million.

    Losers

    • Ainos (NASDAQ:AIMD) shares fell 15.6% to $1.73 during Monday's pre-market session. The company's market cap stands at $8.0 million. As per the press release, Q4 earnings came out yesterday.
    • Nexalin Technology (NASDAQ:NXL) shares decreased by 11.64% to $0.43. The market value of their outstanding shares is at $3.1 million.
    • Fortrea Holdings (NASDAQ:FTRE) shares fell 10.32% to $33.03. The market value of their outstanding shares is at $2.9 billion. As per the press release, Q4 earnings came out today.
    • Avenue Therapeutics (NASDAQ:ATXI) stock fell 9.64% to $0.17. The company's market cap stands at $6.4 million.
    • Indaptus Therapeutics (NASDAQ:INDP) stock fell 9.31% to $1.95. The market value of their outstanding shares is at $16.3 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares fell 7.69% to $0.25. The company's market cap stands at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $APRE
    $ATXI
    $DYAI

    CompanyDatePrice TargetRatingAnalyst
    Fortrea Holdings Inc.
    $FTRE
    1/8/2026$22.00Hold → Buy
    Truist
    Fortrea Holdings Inc.
    $FTRE
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    Fortrea Holdings Inc.
    $FTRE
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    Fortrea Holdings Inc.
    $FTRE
    12/11/2025$21.00Neutral → Buy
    Citigroup
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    Fortrea Holdings Inc.
    $FTRE
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Barclays with a new price target

    Barclays upgraded Fortrea from Underweight to Equal Weight and set a new price target of $15.00

    12/15/25 9:05:06 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:25:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    SEC Filings

    View All

    Indaptus Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Financial Statements and Exhibits

    8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    2/27/26 4:05:49 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/27/26 9:18:59 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/27/26 6:11:44 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

    Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping regenerative medicine[1]. CAR T-cell therapy alone is valued at nearly $7 billion this year, expanding at an 18% compound annual growth rate as off-the-shelf platforms eliminate the logistical barriers that once limited patient access[2]. Among the companies advancing next-generation cell-based treatments are Avaí Bio (OTCQB:AVAI), FibroBiologics (NASDAQ:FBLG), Fate Therapeutics (NASDAQ:FATE), Mesoblast (NASDAQ:MESO), and Longeve

    3/3/26 10:02:00 AM ET
    $FATE
    $FBLG
    $LGVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

    JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS ("Inzymes"), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion

    3/2/26 7:20:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Jabbour Jerome D

    4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    2/27/26 4:06:16 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Jabbour Jerome D

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    2/27/26 4:05:14 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Mcmurdo Matthew Charles claimed ownership of 25,000 shares (SEC Form 3)

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    2/26/26 10:57:10 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Leadership Updates

    Live Leadership Updates

    View All

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Financials

    Live finance-specific insights

    View All

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $AIMD
    $APRE
    $ATXI
    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care